Taysha Gene Therapies, Inc. (TSHA) › Shareholders' EquityTaysha Gene Therapies, Inc. (TSHA) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$135.0K2020: $251.30M2021: $95.38M2022: $949.0K2023: $74.94M2024: $71.53M2025: $246.94M$246.94M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$246.94M+245.2%2024$71.53M-4.6%2023$74.94M+7796.4%2022$949.0K-99.0%2021$95.38M-62.0%2020$251.30M+186249.6%2019-$135.0K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share